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AssessmeNt of outPAtieNt PhysiotherAPy services iN DiseAses of the 
Nervous system iN huNgAry
Molics B.1, Hanzel A.1, Kiss G.1, Járomi M.1, Cs. Horváth Z.2, Sebestyén A.3, Boncz I.1
1University of Pécs, Pécs, Hungary, 2National Institute for Quality- and Organizational 
Development in Healthcare and Medicines, Pécs, Hungary, 3National Health Insurance Fund 
Administration, Pécs, Hungary
Objectives: The purpose of our study is to assess the frequency related to Diseases 
of the nervous system within out-patient care and determine the total health care 
expenses of them in Hungary in 2009. METHODS: CONCLUSIONS:  MethOds: Data 
were derived from the nationwidewide database of Hungarian National Health 
Insurance Fund Administration (NHIFA), based on official reports of outpatient care 
institutes. The 151 different types of treatment codes are listed in the chapter of 
the Guidelines of NHIFA for `Physiotherapists, massage-therapists, conductors and 
other physiotherapy practices`. The diseases of the nervous system are listed in 
the International Classification of Diseases (ICD) with code of G00-G99.  Results: 
Diseases of the nervous system account for 1.331.675 cases in the annual number 
of the physiotherapy-related activities (32318413 cases) showing an approximately 
4,12% prevalence. The following top-10 medical procedure were responsible for 48.48% 
(645562) of total activities: individual training (7.79 %), passive motion therapy on mul-
tiple limbs (6.24%),selective nerve stimulation therapy (5.89%), muscle strengthening 
exercise (5.82%), training for circulation improvement (4.6%), parts of the body per 
individual physiotherapy (4.19%), ergotherapy (3.78%), exercise to prevention of car-
diovascular complications (3.68%), Hand massage (3.53%), electrotherapy - facial nerve 
(2.96%). The total financial cost of all of the physiotherapeutic treatments provided in 
diseases of the nervous system was 388 million Hungarian Forint (1.25 million Euro) 
health insurance subsidy in 2009. cOnclusiOns: The 20 most frequent treatments 
accounts for 71.72 % (955073) of total services. The passive procedures are more com-
mon than the active in the 20 most commonly used activities list. Our results could 
be extremely useful for economic evaluation of the health care system and in the 
financial planning of the treatments of the studied diseases of the nervous system.
PND11
reversAl of chroNic fAtigue iNDuceD AlterAtioNs by sesAmol 
iN mice: eviDeNce for iNvolvemeNt of oxiDAtive stress AND 
iNflAmmAtory PAthwAy
Nayak P.G., Talwar S., Bansal P., Mudgal J., Nandakumar K., Pai K.S.R.
Manipal University, Manipal, India
Objectives: A wide body of literature suggest in vivo neuroprotective, antioxidant, 
anti-inflammatory and anti-ageing properties of Sesamol. This study was aimed 
to elucidate the protective effect of sesamol in experimental model of chronic 
fatigue syndrome (CFS). MethOds: Firstly, Sesamol was tested for its antidepres-
sant potential in mouse models using forced swim test (FST) and tail suspension 
test (TST). Later, Sesamol was examined in mouse model of chronic stress fatigue 
induced by chronic forced swimming for 15 days. Brain biochemical [superoxide 
dismutase (SOD), glutathione-S-transferase (GST), glutathione (GSH), lipid peroxi-
dation and nitrite levels) and plasma cytokines [tumour necrosis factor α (TNF-α ) 
and interleukin 6 (IL-6)] levels were assessed to correlate the possible mechanism 
of action associated with fatigue symptoms. Further, adrenal ascorbic acid meas-
urement was done to correlate corticosterone levels. Results: Mice administered 
with sesamol showed significant decrease in immobility time in acute FST and 
TST. Sesamol significantly attenuated progression of CFS in experimental model as 
compared to control. Sesamol also corrected the other cognitive deficits (locomo-
tor activity, motor activity, memory retention, hyperalgesia) associated with CFS. 
Furthermore, it rectified the diminished levels of antioxidant enzymes such as SOD, 
GST and GSH in brain and altered levels of proinflammatory cytokines (TNF-α and 
IL-6). cOnclusiOns: This finding suggests that anti-fatigue activity of sesamol 
against chronic induced fatigue in mice. The present outcome offers a therapeutic 
application of sesamol against CFS and also offers the scope for its development 
against neuropsychiatric disorders.
uriNAry/KiDNey DisorDers – clinical outcomes studies
PuK1
tADAlAfil iN beNigN ProstAtic hyPerPlAsiA: Protocol for the 
systemAtic review of ADverse eveNts
Singh A., Jha R.K., Kapoor A., Gupta J.
Optum Global Solutions, Noida, India
Objectives: Benign prostatic hyperplasia (BPH) is an age related disorder, however 
its symptoms begin to appear in some men as early as age 40 years. As per estimates 
every second person has BPH by the age of 60 and 90% of individuals develop BPH 
by 85 years. Tadalafil is a selective PDE5 enzyme inhibitor approved to treat men 
with BPH. The aim is to systematically review the medical literature for randomized 
control trial and identify the adverse events (AE) associated with tadalafil use in 
BPH. MethOds: All published randomized controlled trials (RCTs) comparing tada-
lafil with a placebo or active interventions for the treatment of BPH with or without 
any co-morbidity (such as but not limited to erectile dysfunction) were sought from 
PubMed, EMBASE, Cochrane Library, and Google Scholar. Abstracts, titles and then 
the full-text manuscripts of all selected articles will be retrieved and assessed by 
two independent reviewers against the eligibility criteria. Disagreements over study 
inclusion will be resolved through discussion. A pre-designed data extraction form 
will be used by two reviewers for the extraction of AE and other study findings. 
Cochrane risk of bias assessment checklist will be used for the risk of bias assess-
ment. An Excel spreadsheet will be used to extract data from the selected articles. 
Descriptive and quantitative data synthesis will be done for AE reported in all the 
studies. Meta-analysis will be performed using RevMan (v5.0). Results: Though 
there are several studies assessing tadalafil use in erectile dysfunction, a system-
atic review/meta-analysis of the evidence reporting its AE profile when used for 
NeurologicAl DisorDers – health care use & Policy studies
PND7
imPAct of coPAymeNt reDuctioN or exemPtioN ProgrAmme oN 
geNeric Drug utilisAtioN: the sPecifieD DiseAse treAtmeNt reseArch 
ProgrAmme iN JAPAN
Tomita N., Kanatani Y.
National Institute of Public Health, Saitama, Japan
Objectives: In Japan, the Specified Disease Treatment Research Programme pro-
vides copayment reduction or exemption for patients with 56 designated rare 
and intractable diseases/syndromes according to disease severity and patients’ 
income levels. The objective of this study is to examine the impact of the Specified 
Disease Treatment Research Programme on generic drug utilisation under the fee-
for-service payment system. MethOds: We extracted and analysed claims data 
with indication for Parkinson’s disease, which is subject to the Specified Disease 
Treatment Research Programme, from the Social Health Insurance claims data 
processed from February to April 2011. Extracted data were analysed in terms of 
patients’ age and income levels, types of public subsidy, prescribed places (clinic/
hospital or pharmacy) and pharmacologic classes. Results: During the three 
months, cumulative total number of 72,145 patients in Social Health Insurance 
programme were prescribed drugs for Parkinson’s disease, of which 10,013 were 
entitled to the Specified Disease Treatment Research Programme. Overall average 
generic utilisation rate is 15.46% on a volume basis. Average generic utilisation rate 
for those entitled to the Specified Disease Treatment Research Programme is 4.04%, 
whilst for patients eligible for medical assistance programme is 21.75%. Generic 
utilisation is fewer in the elderly than in the younger generation. cOnclusiOns: 
Our study finds low generic utilization rate for patients with Parkinson’s disease 
entitled to the Specified Disease Treatment Research Programme. This might be 
suggesting that without mandatory clinical guidelines nor guidance for generic 
substitution, the Specified Disease Treatment Research Programme has been pro-
moted branded prescribing under the fee-for-service system. Additional studies 
with other designated rare and intractable diseases/syndromes are expected to 
generalise the study result.
PND8
Acetyl-l-cArNitiNe for the treAtmeNt of PeriPherAl NeuroPAthic 
PAiN: A systemAtic review AND metA-ANAlysis
Li S., Li Q., Li Y., Hou Q., Li L., Yu C., Sun X., Tian H.
West China Hospital, Sichuan University, Chengdu, China
Objectives: Acetyl-L-carnitine (ALC), as a constructive component in fatty acid 
metabolism, is considered a potential agent for peripheral neuropathic pain (PNP). 
We aimed to access the efficacy and safety of ALC for the treatment of patients 
with PNP. MethOds: We searched PubMed up to March 2014 for randomized 
controlled trials (RCTs) comparing ALC with placebo or other active medications 
in diabetic and non-diabetic PNP patients. Two reviewers independently screened 
for eligible studies, assessed risk of bias, and extracted data. Mean difference (MD) 
and 95% confidence interval (CI) were used for pooling continuous data. Results: 
Four RCTs compared ALC with placebo and reported in 3 articles (n = 523) were 
included. Compared with placebo, ALC significantly reduced Visual Analogue Scale 
(VAS) of PNP patients (MD, 1.28; 95%CI, 0.93-1.64, P < 0.00001). In the subgroup 
analysis, the efficacy of ALC on VAS was similar in different administration route 
(intramuscular-oral sequential subgroup: MD, 1.19; 95% CI, 0.34-2.04, P = 0.006; oral 
only subgroup: pooled MD, 1.15; 95% CI, 0.33-1.96, P = 0.006), and ALC appeared 
more effective in diabetic PNP patients than non-diabetic PNP patients (diabetic 
subgroup: MD, 1.47; 95% CI, 1.06-1.87, P < 0.00001; non-diabetic subgroup: MD, 0.71; 
95% CI, -0.01-1.43, P = 0.05). No severe adverse events related to ALC were reported. 
The common adverse events were pain, headache, paraesthesia, hyperesthesia, 
retching, biliary colic and gastrointestinal disorders. The rates of total adverse 
events were similar in ALC and control group. cOnclusiOns: ALC could reduce 
VAS in PNP patients with acceptable safety. However, further trials with larger 
population and longer follow-up are required to confirm these findings.
PND9
Age AND geNDer DistributioN of outPAtieNt cAre PhysiotherAPy 
services for cerebrAl PAlsy AND other PArAlytic syNDromes  
iN huNgAry
Molics B., Járomi M., Endrei D., Zemplényi A., Boncz I.
University of Pécs, Pécs, Hungary
Objectives: The aim of our study is to assess the utilization of out-patient care 
physiotherapy services related to cerebral palsy and other paralytic syndromes 
according to age and gender. MethOds: The data come from the financial data 
base of the National Health Insurance Fund Administration involving the year 
of 2009. The activity list was provided by the rulebook on the application of the 
activity code list in out-patient care. The Cerebral Palsy and other paralytic 
syndromes are listed in the International Classification of Diseases (ICD) with 
code of G80-G83. The number of cases in physiotherapy activities were deter-
mined per 10000 persons by age and gender in outpatient care, 2009. Results: 
Diseases of the nervous system account for 1331675 cases in the annual number 
of the physiotherapy-related activities (32318413 cases) showing an approxi-
mately 4.12% prevalence. The prevalence of the Cerebral Palsy and other para-
lytic syndromes were 31.56% in the group of of diseases of the nervous system. 
The average number of cases of physiotherapy activities per 10000 persons 
accounted for 433 cases in 2009. The average number of cases per 10000 persons 
for males and females were 508 cases for males and 364 cases for females. 
The high number of physiotherapy treatment is provided for both gender in 
the youngest age group and 60-74 age groups in male and 70-84 age groups 
in female. cOnclusiOns: The cerebral palsy and other paralytic syndromes 
at the diseases of the nervous system show high prevalence, indicating the 
importance of prevention.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  A811
pro-inflammatory cytokine and chemokine production by primary renal tubular epi-
thelial cells and monocytes/macrophages. cOnclusiOns: These findings demon-
strate that administration of forskolin is beneficial for controlling the development 
of UPEC mediated acute pyelonephritis in mice. The protective effect of forskolin 
(via cAMP activation) in this experimental acute pyelonephritis can be explained at 
least in part by limiting excessive inflammatory responses through acting on both 
renal parenchymal and inflammatory cells.
PuK6
c5A recePtor ANtAgoNist Protects mice from uroPAthogeNic 
escherichiA coli-iNDuceD KiDNey iNfectioN
Zhang T.1, Wu K.Y.1, Duan Z.Y.1, Lin Y.1, Gui B.S.1, Liu D.2, Li K.1
1The Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, China, 2The 
Fifth Hospital of Xi’an, Xi’an, China
Objectives: To determine if blocking C5aR could effectively protect mice from UPEC 
induced kidney infection. MethOds: A well-established mouse model of ascending 
UTI leading to kidney infection was employed. C5aR antagonist (C5aRa, W54011) 
(250mg/kg) was given before the induction of infection by i.p. injection. Kidney 
infection was assessed in C5aRa or control reagent treated mice at 6, 24, 72h after 
bladder inoculation of UPEC. Bacteria load in kidneys was analysed by the agar plate 
assay. Tissue damage was assessed by histopathology. Leukocytes infiltration was 
analysed by immunochemical staining, tissue MPO activity assay and flow cytom-
etry. Renal synthesis of cytokines/chemokines was analysed by RT-PCR. Results: 
Compared to control reagent treated mice, C5aRa treated mice, either from B6 or 
BALB/c background, exhibited significantly lower rates of kidney infection (B6: 37.5% 
vs 100% [n= 16], BALB/c: 26% vs 87% [n= 15]), reduced kidney tissue damage and gene 
expression of KC, IL-6 and TNF-α in kidney tissues. The reduction of kidney infection 
and tissue damage resulting from C5aR blockade was more profound at 48h and 
72h post infection. C5aR blockade led a small reduction of neutrophil infiltration at 
6h, but had no apparent effect on late time point. cOnclusiOns: C5aR blockade 
effectively protected mice from UPEC-induced kidney infection suggesting that C5aR 
signal is a critical pathogenic factor in UTIs, thus representing a promising target 
for treating or preventing human UTIs.
uriNAry/KiDNey DisorDers – cost studies
PuK7
buDget imPAct ANAlysis of PeritoNeAl DiAlysis versus. coNveNtioNAl 
iN-ceNter hemoDiAlysis iN mAlAysiA
Bavanandan S.1, Ahmad G.1, Teo A.H.2, Chen L.3, Liu F.X.4
1Hospital Kuala Lumpur, Kuala Lumpur, Malaysia, 2Baxter Healthcare (M) Sdn Bhd, Kuala 
Lumpur, Malaysia, 3Baxter Asia Pacific, Shanghai, China, 4Baxter Healthcare Corporation, 
Deerfield, IL, USA
Objectives: The increasing prevalence of patients with end-stage renal disease 
in Malaysia is driving up the costs of dialysis care dramatically. Several studies 
have projected significant cost savings by increasing the proportion of patients 
on peritoneal dialysis (PD). This study investigates the five-year health care 
budget impact of variable distribution of adult patients treated with PD and in-
center hemodialysis (ICHD) on government funding in Malaysia. MethOds: An 
Excel®-based budget impact model was constructed to assess dialysis-associ-
ated costs when changing dialysis modalities between PD and ICHD. The model 
incorporates the current modality distribution and accounts for Malaysian govern-
ment dialysis payments and EPO costs. Epidemiological data, including dialysis 
prevalence, incidence, mortality, and transplant rate from Malaysian renal registry 
reports, were used to estimate the dialysis patient population for the next five years. 
The baseline scenario assumed a stable distribution of PD (8%) and ICHD (92%) 
over five years. Alternative scenarios included the prevalence of PD increased by 
2.5%, 5.0%, and 7.5% or decreased 1% yearly over five years. All four scenarios were 
accompanied with commensurate changes in ICHD. Results: Under the current 
best available cost information, an increase in the prevalent PD population from 8% 
in 2014 to 18%, 28%, or 38% in 2018 is predicted to result in five-year cumulative sav-
ings for the Malaysian government of RM13.9 million, RM27.9 million, and RM41.96 
million, respectively. If the prevalent PD population were to decrease from 8% in 
2014 to 4.0% by 2018, the total expenditure for dialysis treatments would increase 
by RM5.6 million over the next five years. cOnclusiOns: Under the best available 
cost information associated with PD and HD paid by the Malaysian government, 
increasing the proportion of patients on PD could result in reduction in dialysis-
associated costs in the future.
PuK8
fiNANciAl imPlicAtioNs to tAiwAN heAlth system from chANgiNg the 
DiAlysis moDAlity mix
Yang W.C.1, Hsu C.C.2, Liu F.X.3
1Taipei Veterans General Hospital, Taipei, Taiwan, 2National Health Research Institutes, Taipei, 
Taiwan, 3Baxter Healthcare Corporation, Deerfield, IL, USA
Objectives: In 2012, 0.3% of Taiwan end-stage renal disease (ESRD) patients 
accounted for 6.64% of National Health Insurance (NHI) dialysis spending. 
We investigated the five-year financial impact of changing the distribution of 
patients undergoing peritoneal dialysis (PD) and in-center hemodialysis (ICHD) 
in Taiwan. MethOds: An Excel®-based budget impact model was constructed to 
assess dialysis-associated costs. The model incorporates Taiwan current modal-
ity distribution and accounts for ESRD outpatient and inpatient total health care 
cost. Epidemiological data of ESRD patients from 2000 to 2011 was acquired from 
Taiwan Renal Data System by Taiwan Society of Nephrology. The transplant rate 
was provided by experts in the field. These data were used to estimate dialysis 
population for the next five years. Dialysis costs were obtained by National Health 
Research Institutes (NHRI) Databases for 2008. The baseline scenario assumed a 
stable distribution of PD (10%) and ICHD (90%) over five years. Four scenarios, includ-
the treatment of BPH is lacking. This systematic review registered with PROSPERO 
(registration number: CRD42014007248) aims to provide the evidence for the AE 
associate with tadalafil use in BPH indication. cOnclusiOns: Tadalafil use in BPH 
has now been increasing over the years. The data from published RCTs will help to 
identify the AE associated with its use.
PuK2
PrevAleNce AND AssociAteD comPlicAtioN of Acute KiDNey iNJury 
AmoNg DeNgue PAtieNts
Khan Y.1, Sarriff A.1, Khan A.H.2, Adnan A.S.3, Jummat F.4, Mallhi T.H.1
1Universiti Sains Malaysia, Penang, Malaysia, 2Universiti Sains Malaysia, Minden, Malaysia, 
3CKD Resource Centre, Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia, 
4School of Medical Sciences, HUSM, Kota Bharu, Kelantan, Malaysia
Objectives: Dengue fever is a mosquito borne infectious disease that is mainly 
prevalent in tropical and subtropical zones of the world. One of the potential 
complications of dengue fever is acute kidney injury (AKI). Current study aims to 
assess the incidence and risk factors for AKI among dengue patients.  MethOds: 
A retrospective review of medical records of dengue infected patients enrolled 
from May 2005 to December 2013 was conducted at a tertiary care hospital in 
Kelantan. Results: Total 124 patient records (male: 63, female: 61) with mean 
age of 29.57± 15.09 were reviewed retrospectively. Out of 124 patients, 104 (83.9%) 
suffered with classical DF, 19 (15.3%) with dengue hemorrhagic fever (DHF) while 
only 1(0.8%) with Dengue shock syndrome (DSS).The prevalence of AKI among 
Dengue patients was found to be 7.2 % (9 patients). On the basis of Acute Kidney 
Injury Network (AKIN) criteria, 2(22%) had stage 1 AKI while remaining 7 (78%) 
had stage 2 AKI. For the purpose of analysis of risk factors for AKI, patients were 
categorized into group I (with AKI) and group II (without AKI). Mann Whitney “U” 
test was used to compare differences between groups. A higher serum creatinine 
(112.39 vs. 56.87; p:0.001), bilirubin (70.81 vs. 48.73; p:0.038), urea (104.50 vs. 58.08; 
p:0.001), WBC (92.25 vs. 59.90; p:0.013) and Hb (90.91 vs. 60.04; p:0.021) levels were 
observed among AKI dengue patients. Though the duration of hospital stay of 
group I was more than group II, but this difference was statistically insignifi-
cant (I=77.33, II= 61.34; p: 0.192). cOnclusiOns: AKI is a least studied and poorly 
understood complication of dengue fever. Such patients are at verge of developing 
DHS/DSS resulting in complicated clinical course and increased mortality. A cau-
tious diagnosis and timely management should be the first and foremost step for 
management of such patients.
PuK3
ePiDemiology of eND stAge reNAl DiseAse PAtieNts oN hemoDiAlysis 
for hosPitAl reADmissioNs
Kumar P.
Manipal University, Manipal, India
Objectives: The study aims to determine the different epidemiological factors 
responsible for the cause of hospital readmissions in chronic hemodialysis (HD) 
patients. MethOds: Reviewed data of 170 patients with 124 male and 46 female 
patients receiving maintenance HD twice weekly schedule on a Mon/Thu, Tue/Fri, 
Wed/Sat with prevalent adult’s HD patients on period from 1st Jan to Dec 31, 2010 
or continued until close at death, modality change, deviation from HD schedule not 
during a hospital stay, loss to follow-up. Eligible patients were actively recruited who 
were on chronic HD fulfilling the inclusion criteria. ICD-9-CM diagnosis codes were 
used. Results: A total of 170 patients with End-stage renal disease (ESRD) on chronic 
HD included the study cohort. The mean age was 52.4±11.6 years; 27% were women 
with a mean year of patients on hemodialysis of 3.2±2.6. Hypertension 29.3% and 
hypertension with diabetes 26.4% were the leading cause of ESRD and least cause of 
renal failure was seen with polycystic kidney disease, Glomerulonephritis, Interstitial 
nephritis, and others. Hospital readmission was commonly for cardiovascular complications 
62% to infections 31% and other 7%. IHD, Stroke and Congestive heart failure lead to read-
mission and with infection of AV fistula 66% were more commonly seen compared to 
Catheterization. cOnclusiOns: Hypertension is the leading cause for ESRD and car-
diovascular complications were associated with elevated hospital readmission in addition 
to infection. AV fistula is the other common source of infection leading to readmission.
PuK5
ActivAtioN of eNDogeNous ANti-iNflAmmAtory meDiAtor cyclic 
AmP coNfers ProtectioN iN muriNe Acute PyeloNePhritis iNDuceD by 
uroPAthogeNic e coli
Lin Y.1, Gui B.S.1, Wei Y.1, Zhang T.1, Liu D.2, Li K.1
1The Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, China, 2The 
Fifth Hospital of Xi’an, Xi’an, China
Objectives: To investigate the effect of forskolin, on susceptibility/severity of acute 
pyelonephritis and innate immune responses to pathogen using an established 
experimental model of ascending urinary tract infection and primary cell cultures 
(i.e. renal tubular epithelial cells, monocytes/macrophages). MethOds: Forskolin 
is produced by the Indian Coleus plant (Coleus forskohlii), which is commonly used 
to raise levels of cyclic AMP (cAMP) in the study and research of cell physiology. 
Forkolin (250mg/kg) was given before the induction of infection by i.p. injection. 
Kidney infection was assessed in forskolin or control reagent treated mice at 6, 24, 
48h after bladder inoculation of UPEC (J96). Bacteria load in kidneys was analyzed 
by the agar plate assay. Tissue damage was assessed by histopathology. Leukocytes 
infiltration was analysed by immunochemical staining, tissue MPO activity assay 
and flow cytometry. Renal synthesis of cytokines/chemokines was analysed by 
RT-PCR. Results: Administration of forskolin significantly reduced bacteria load 
in kidneys and renal tissue damage at both 6 and 24h time points by 10 folds, this 
was associated with reduced intrarenal production of pro-inflammatory cytokines 
and chemokines (e.g. TNF-α , IL-1β , KC, MCP-1) and attenuated intrarenal infiltra-
tion and accumulation of leukocytes (i.e. CD45+. Gr-1+, F4/80+) as well as intrarenal 
myeloperoxidase (MPO) activity. In vitro, forskolinI inhibited LPS or UPEC mediated 
